Last reviewed · How we verify
NCT04113993
Bazedoxifene -Treatment for Women With Schizophrenia
Phase 4 trial testing Bazedoxifene Acetate in Schizophrenia in 160 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | The Alfred |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 160 |
| Start date | 7 October 2019 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Bazedoxifene Acetate (Bazedoxifene Acetate) — full drug profile →
- Placebo
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Schizophreniform Disorders — all drugs for Schizophreniform Disorders →
- Schizo Affective Disorder — all drugs for Schizo Affective Disorder →
Sponsor
The Alfred — full company profile →
Who can join
Adults 18 to 65, female only, with Schizophrenia or Schizophreniform Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the effect of adjunctive bazedoxifene - a selective estrogen receptor modulator (SERM) in a double blind, placebo-controlled adjunctive study in the treatment of women with schizophrenia. All patients receive standardized antipsychotic medication.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04113993
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bazedoxifene Acetate
Trials testing the same drug.
- NCT04002934 — Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis · Phase 2 · completed
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other The Alfred trials
Trials by the same sponsor.
- NCT07430267 — Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion · NA · not yet recruiting
- NCT05591677 — D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT) · Phase 2 · active not recruiting
- NCT03095859 — Post-operative, Inpatient Rehabilitation After Lung Transplant Evaluation · NA · completed
- NCT03026985 — Acute Skeletal Muscle Wasting and Relation to Physical Function in Patients Requiring ECMO · completed
- NCT03000933 — Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04113993 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Alfred
- Last refreshed: 28 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04113993.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing